Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;188(3):211-219.
doi: 10.1007/s11046-023-00713-5. Epub 2023 Apr 17.

Aspergillus Species Causing Invasive Fungal Disease in Queensland, Australia

Adam G Stewart  1   2   3 , Burcu Isler  4   5 , Peter Simos  5 , Drew Farquhar  6 , Narelle George  7 , Mila Golmayo  7 , Claire Heney  7
Affiliations

Aspergillus Species Causing Invasive Fungal Disease in Queensland, Australia

Adam G Stewart et al. Mycopathologia. 2023 Jun.

Abstract

Background: Aspergillus species are important causes of invasive fungal disease, particularly among those with an impaired immune system. Increasing reports have revealed a rising incidence of antifungal drug resistance among Aspergillus spp., particularly among cryptic species. Understanding local antifungal susceptibility patterns is paramount to delivering optimal clinical care.

Methods: Aspergillus spp. recovered from clinical specimens between 2000 and 2021 from Pathology Queensland were collected. Aspergillus spp. were identified routinely morphologically, and where there was ambiguity or a lack of sporulation, by sequencing of the internal transcribed spacer (ITS) region. All Aspergillus spp. that underwent antifungal susceptibility testing according to the CLSI M38-A3 method and were recorded and included in the study. Amphotericin B, voriconazole, posaconazole, isavuconazole, micafungin, caspofungin, and anidulafungin were tested. Pathology Queensland services all public healthcare facilities in Queensland, Australia.

Results: 236 Aspergillus spp. were identified from clinical specimens during the study period. The most frequent species identified were Aspergillus section Fumigati (n = 119), Aspergillus section Flavi (n = 35), Aspergillus terreus (n = 32) and Aspergillus niger (n = 29). Overall, MIC50/90 values for voriconazole, posaconazole, itraconazole, and isavuconazole were 0.25/1, 0.25/0.5, 0.25/0.5, and 0.5/2 mg/L respectively. Echinocandins demonstrated low MIC values overall with micafungin and anidulafungin both having an MIC50/90 of 0.015/0.03 mg/L. A total of 15 cryptic species were identified; high triazole MIC values were observed with a voriconazole MIC50/90 of 2/8 mg/L. From 2017 to 2021 we observed an increase in incidence of isolates with high voriconazole MIC values. There was no difference in voriconazole MIC values between Aspergillus spp. acquired in North Queensland when compared to Southeast Queensland, Australia.

Conclusion: Increasing reports of antifungal resistance among Aspergillus spp. is concerning and warrants further investigation both locally and worldwide. Active surveillance of both the emergence of different Aspergillus spp. and changes in antifungal susceptibility patterns over time is crucial to informing clinicians and treatment guidelines.

Keywords: Antifungal susceptibility testing; Aspergillus species; Azole resistance.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interest to disclose.

Figures

Fig. 1
Fig. 1
Voriconazole MIC values in Aspergillus species (n = 150) according to year (2017–2021) in Queensland, Australia
Fig. 2
Fig. 2
Anidulafungin MEC values in Aspergillus species (n = 150) according to year (2017–2021) in Queensland, Australia
Fig. 3
Fig. 3
Voriconazole MIC values in Aspergillus species (n = 236) according to geographical location (North Queensland versus Southeast Queensland)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lortholary O, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007) Clin Microbiol Infect. 2011;17(12):1882–1889. doi: 10.1111/j.1469-0691.2011.03548.x. - DOI - PubMed
    1. Bitar D, et al. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis. 2014;20(7):1149–1155. doi: 10.3201/eid2007.140087. - DOI - PMC - PubMed
    1. Patterson TF, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi: 10.1093/cid/ciw326. - DOI - PMC - PubMed
    1. Ullmann AJ, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38. doi: 10.1016/j.cmi.2018.01.002. - DOI - PubMed
    1. Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49(Suppl 1):S82–S89. doi: 10.3109/13693786.2010.499916. - DOI - PubMed